Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Julie Hafner
Tanzania
Research Article
EDDR1 is a Potential Immunotherapeutic Antigen in Ovarian, Breast, and Prostate Cancer
Author(s): Gomathinayagam Sinnathamby, Jennifer Zerfass, Julie Hafner, Peter Block, Zacharie Nickens, Amy Hobeika, Angeles Alvarez Secord, H. Kim Lyerly, Michael A. Morse and Ramila Philip
Gomathinayagam Sinnathamby, Jennifer Zerfass, Julie Hafner, Peter Block, Zacharie Nickens, Amy Hobeika, Angeles Alvarez Secord, H. Kim Lyerly, Michael A. Morse and Ramila Philip
Selection of suitable antigens, preferably targets for cell mediated and humoral immune response is a critical step in the development of cancer vaccines. Cell surface proteins that are over-expressed in cancer cells thus constitute a very attractive class of antigens that can be targeted for effective cancer immunotherapy. Toward this goal, we characterized the relevance of Epithelial Discoidin Domain Receptor 1 (EDDR1) for such targeted therapeutics. EDDR1, a membrane expressed protein associated with adhesion, has recently emerged as a new therapeutic target in several tumor types. In the present study, we analyzed the expression profile of EDDR1 in a variety of normal and cancer cells of human origin by flow cytometry as well as immunohistochemistry. EDDR1 was found to be abundantly expressed on the surface of ovarian, prostate and breast cancer cells but not on the normal counter.. View More»
DOI:
10.4172/2155-9899.1000106